<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="822">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542876</url>
  </required_header>
  <id_info>
    <org_study_id>AYU/DSSR/03</org_study_id>
    <nct_id>NCT04542876</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection</brief_title>
  <official_title>Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarogyam UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarogyam UK</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence of asymptomatic patients poses a significant challenge to the prevention and
      treatment of the epidemic.There have not been any treatment options that reduce the viral
      load or preventive options that reduce the risk of developing severe conditions.Therefore,
      present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in
      asymptomatic patients with COVID-19
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">August 18, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic clearance</measure>
    <time_frame>14 days</time_frame>
    <description>Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Stay</measure>
    <time_frame>14 days</time_frame>
    <description>Total duration of stay in hospital for complete recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant adverse effects</measure>
    <time_frame>14 days</time_frame>
    <description>Clinically relevant adverse effects of Guduchi Ghan Vati were reported using Adverse Drug Reaction reporting form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>change from baseline to 14 days</time_frame>
    <description>Routine blood tests were performed to assess complete blood counts, blood biochemistry parameters {Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin} and immunoglobulines.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Ayurveda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guduchi Ghan Vati</intervention_name>
    <description>Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.</description>
    <arm_group_label>Ayurveda</arm_group_label>
    <other_name>Giloya</other_name>
    <other_name>Amrita</other_name>
    <other_name>Tinosporia Cordifolus</other_name>
    <other_name>Guduchi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All hospitalised cases above 18 years of age,

          -  Diagnosed with Covid-19

          -  Asymptomatic at the time of admission

          -  Agree to give consent

        Exclusion Criteria:

          -  Symptoms relating to Covid-19

          -  Severe vomiting

          -  Respiratory failure or requiring mechanical ventilation

          -  Patients having alanine transaminase (ALT) or aspartate transaminase (AST) &gt; 5 times
             the upper range of normal limits

          -  Patients with Covid-19 in critical condition or ARDS or NIAD 8 -point ordinal score-2

          -  Patients with uncontrolled diabetes mellitus

          -  Malignant,

          -  Chronic renal failure or

          -  On immunosuppressive medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Kumar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neha Sharma</last_name>
    <role>Study Director</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University</name>
      <address>
        <city>Jodhpur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

